Senior Partner Emeritus
Grateful for your mentorship
Dr. John Zabriskie
Co-Founder, Senior Partner Emeritus
Ronald E. Cape PhD, MBA
Senior Partner Emeritus
Dr. Ronald E. Cape is a Senior Partner Emeritus at Puretech and sevred as Director at PureTech. Dr. Cape is recognized as one of the fathers of the biotechnology industry. He Co-Founded Cetus Corporation in 1971, where he served as the Chairman for 20 years and the Chief Executive Officer for 13 years until the company merged with Chiron Corporation. He was a Founding Member of the Industrial Biotechnology Association, where he served as the President from 1983 to 1985. Since 1991, Dr. Cape has been an investor in the field of biotechnology and a board member of various companies. He was the founding Chairman of Darwin Molecular Corporation, which was later sold to Chiroscience plc, and is the Chairman and Director of Caprion, Inc., Cellicon Biotechnologies, and several other biotechnology companies. Dr. Cape serves as the Chairman at Neugenesis Corp. and Ellipsis Biotherapeutics Corp. He has been a Director at EntreMed, Inc., since June 18, 2003 and a Member of its Corporate Governance and Nominating Committees. Dr. Cape also serves as a Director for several privately held biotechnology companies, including Caprion Pharmaceuticals, Inc., Gelesis Inc., Ellipsis Biotherapeutics Corporation, Sunol Molecular Corporation, Neurobiological Technologies Inc. since November 2004, National Science & Technology Medals Foundation, Chiroscience plc., Cogito, NeuroVir, Inc., and Neugenesis Corp.
Dr. Cape is a fellow of the American Academy of Arts and Sciences, tAmerican Academy of Microbiology, and the American Association for the Advancement of Science. He serves as a Member of AdvisBoard (U.S.) at Earlybird Venture Capital GmbH & Co. KG. He serves as a Member of Scientific and Technology Advisor at Spartan Bioscience Inc. Dr. Cape serves on the Editorial Advisory Board at BioCentury and the Scientific Advisory Board at the Canadian Medical Discoveries Fund, Inc. He served as a Director at GlycoDesign Inc., Princeton University, Rockefeller Princeton University, Rockefeller University, and the Whitehead Institute at MIT.
Dr. Cape is a Co-Editor of Biotechnology: The Science and the Business. He is the recipient of many awards and has held dozens of prestigious board positions in the public and private sectors. He is the recipient of many awards and has held dozens of prestigious board positions in the public and private sectors. He holds an A.B. degree in Chemistry from Princeton University in 1953 and an M.B.A. degree from Harvard University in 1955. Dr. Cape holds a Ph.D. degree in Biochemistry from McGill University in 1967 and did post-doctoral research at University of California at Berkley on a Centennial Fellowship of the Medical Research Council of Canada.
Frank Douglas, MD, PhD
Senior Partner Emeritus
Dr. Douglas is a Senior Partner Emeritus at PureTech. He is President and CEO of Austen BioInnovation Institute in Akron, Ohio, a best-in-class model for the future of health care delivery and innovation. Previously, he was Professor of the Practice at MIT, the Harvard-MIT Division of Health Sciences & Technology, and Executive Director of the MIT Center for Biomedical Innovation.
Dr. Douglas was also a member of the Board of Management and Executive Vice President, Drug Innovation and Approval, and Chief Scientific Officer of Aventis SA, where he oversaw global pharmaceutical research, development and regulatory activities. Prior to his positions with Aventis, Dr. Douglas was EVP of Global Research at Hoechst Marion Roussel, EVP of Research and Development at Marion Merrel Dow, and SVP & Director of Research at CIBA-GEIGY.
He also served as Chairman of the Executive Committee of the Science and Regulatory Section of the Pharmaceutical Research and Manufacturers Association (PhRMA), has been a member of the Scientific Advisory Board of the U.S. Food and Drug Administration, the Advisory Board of the Paul Ehrlich Foundation, and a member of the Board of Directors of Alantos, Gene Logic, Nitromed Inc., and Archemix Inc. Currently, Dr. Douglas is President and CEO of the Bioinnovation Institute in Akron, and a Kauffman Foundation Senior Fellow. He has received the Lewis B. Russell Memorial Award from the American Heart Association, the J.W. von Goethe Frankfurt University Medal of Honor and was named the recipient of the Global Pharmaceutical R&D Director of the Year Award in 2001, and again in 2004.
Throughout his career Dr. Douglas has led teams that have discovered, developed, or extended the indications of more than 20 drugs. As a senior executive, he pioneered organizational changes that were forerunners in the emerging field of Translational Medicine, and he introduced Chemical Biology Platforms to the pharmaceutical industry. Dr. Douglas received his PhD in physical chemistry and MD from Cornell University.